Fengrui Zhou1, Xin Wang1, Fang Liu1, Qingwei Meng1, Yan Yu2. 1. Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, 150081, Heilongjiang, China. 2. Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, 150081, Heilongjiang, China. Yuyan@ems.hrbmu.edu.cn.
Abstract
PURPOSE: The purpose of this research was to explore the correlation and prognostic significance of FAM83A and programmed cell death-ligand 1 (PD-L1) protein expression in patients with lung adenocarcinoma (LUAD). METHODS: A total of 130 LUAD specimens and 50 normal lung tissue specimens were analyzed for both FAM83A and PD-L1 expression by immunohistochemistry (IHC) analysis. The effect of FAM83A on PD-L1 and ERK pathway was evaluated by RT-PCR and western blot in vitro. RESULTS: Both FAM83A and PD-L1 were upregulated in patients with LUAD and co-expression of them was significantly associated with tumor stage, metastasis and worse survival in LUAD. Multivariate cox regression analysis revealed that co-expression of FAM83A and PD-L1 was an independent prognostic factor impacting survival. Moreover, experiments in vitro showed FAM83A could promote the expression of PD-L1 through the ERK pathway. CONCLUSION: FAM83A and PD-L1 may be potential therapeutic targets for LUAD. Co-expression of FAM83A and PD-L1 in tumor cells was a credible biomarker predictor for worse survival in resected cases. FAM83A may promote the expression of PD-L1 through ERK signaling pathway, thus causing immune escape of tumor.
PURPOSE: The purpose of this research was to explore the correlation and prognostic significance of FAM83A and programmed cell death-ligand 1 (PD-L1) protein expression in patients with lung adenocarcinoma (LUAD). METHODS: A total of 130 LUAD specimens and 50 normal lung tissue specimens were analyzed for both FAM83A and PD-L1 expression by immunohistochemistry (IHC) analysis. The effect of FAM83A on PD-L1 and ERK pathway was evaluated by RT-PCR and western blot in vitro. RESULTS: Both FAM83A and PD-L1 were upregulated in patients with LUAD and co-expression of them was significantly associated with tumor stage, metastasis and worse survival in LUAD. Multivariate cox regression analysis revealed that co-expression of FAM83A and PD-L1 was an independent prognostic factor impacting survival. Moreover, experiments in vitro showed FAM83A could promote the expression of PD-L1 through the ERK pathway. CONCLUSION:FAM83A and PD-L1 may be potential therapeutic targets for LUAD. Co-expression of FAM83A and PD-L1 in tumor cells was a credible biomarker predictor for worse survival in resected cases. FAM83A may promote the expression of PD-L1 through ERK signaling pathway, thus causing immune escape of tumor.
Authors: Ahmed Ghallab; Maiju Myllys; Adrian Friebel; Julia Duda; Karolina Edlund; Emina Halilbasic; Mihael Vucur; Zaynab Hobloss; Lisa Brackhagen; Brigitte Begher-Tibbe; Reham Hassan; Michael Burke; Erhan Genc; Lynn Johann Frohwein; Ute Hofmann; Christian H Holland; Daniela González; Magdalena Keller; Abdel-Latif Seddek; Tahany Abbas; Elsayed S I Mohammed; Andreas Teufel; Timo Itzel; Sarah Metzler; Rosemarie Marchan; Cristina Cadenas; Carsten Watzl; Michael A Nitsche; Franziska Kappenberg; Tom Luedde; Thomas Longerich; Jörg Rahnenführer; Stefan Hoehme; Michael Trauner; Jan G Hengstler Journal: Cells Date: 2021-09-23 Impact factor: 6.600